Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIR: Individualized Antibiotic Therapy Duration in Community-Acquired Pneumonia
2024-516097-30-00Phase 4Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azithromycin in community-acquired pneumonia (CAP) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Cure at Day 15. Planned start Nov 2024; status: authorised.
02
Drugs
azithromycin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2024-516097-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516097-30-00.